1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis - Drugs In Development, 2022, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 21, 12, 2, 35 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Glomerulonephritis - Overview
- Glomerulonephritis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Glomerulonephritis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Glomerulonephritis - Companies Involved in Therapeutics Development
- Glomerulonephritis - Drug Profiles
- Glomerulonephritis - Dormant Projects
- Glomerulonephritis - Discontinued Products
- Glomerulonephritis - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Glomerulonephritis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Glomerulonephritis - Pipeline by AKSO Biopharmaceutical Inc, 2022
- Glomerulonephritis - Pipeline by Alexion Pharmaceuticals Inc, 2022
- Glomerulonephritis - Pipeline by Algomedix Inc, 2022
- Glomerulonephritis - Pipeline by Alnylam Pharmaceuticals Inc, 2022
- Glomerulonephritis - Pipeline by Amyndas Pharmaceuticals LLC, 2022
- Glomerulonephritis - Pipeline by Anagenics Ltd, 2022
- Glomerulonephritis - Pipeline by Angion Biomedica Corp, 2022
- Glomerulonephritis - Pipeline by Apellis Pharmaceuticals Inc, 2022
- Glomerulonephritis - Pipeline by Argenx SE, 2022
- Glomerulonephritis - Pipeline by Arrowhead Pharmaceuticals Inc, 2022
- Glomerulonephritis - Pipeline by Bayer AG, 2022
- Glomerulonephritis - Pipeline by BioCryst Pharmaceuticals Inc, 2022
- Glomerulonephritis - Pipeline by Biogen Inc, 2022
- Glomerulonephritis - Pipeline by Boehringer Ingelheim International GmbH, 2022
- Glomerulonephritis - Pipeline by Cabaletta Bio Inc, 2022
- Glomerulonephritis - Pipeline by Calliditas Therapeutics AB, 2022
- Glomerulonephritis - Pipeline by Ceptur Therapeutics Inc, 2022
- Glomerulonephritis - Pipeline by Certa Therapeutics Pty Ltd, 2022
- Glomerulonephritis - Pipeline by ChemoCentryx Inc, 2022
- Glomerulonephritis - Pipeline by Chinook Therapeutics Inc, 2022
- Glomerulonephritis - Pipeline by Coegin Pharma AS, 2022
- Glomerulonephritis - Pipeline by Cytodesign Inc, 2022
- Glomerulonephritis - Pipeline by Delta 4 GmbH, 2022
- Glomerulonephritis - Pipeline by DiaMedica Therapeutics Inc, 2022
- Glomerulonephritis - Pipeline by Dimerix Ltd, 2022
- Glomerulonephritis - Pipeline by Eledon Pharmaceuticals Inc, 2022
- Glomerulonephritis - Pipeline by Eli Lilly and Co, 2022
- Glomerulonephritis - Pipeline by Ergon Pharmaceuticals LLC, 2022
- Glomerulonephritis - Pipeline by Generian Pharmaceuticals Inc, 2022
- Glomerulonephritis - Pipeline by Goldfinch Bio Inc, 2022
- Glomerulonephritis - Pipeline by HanAll Biopharma Co Ltd, 2022
- Glomerulonephritis - Pipeline by Horizon Therapeutics Plc, 2022
- Glomerulonephritis - Pipeline by IGAN Biosciences Inc, 2022
- Glomerulonephritis - Pipeline by ImmunoWork LLC, 2022
- Glomerulonephritis - Pipeline by Inmagene Biopharmaceuticals Ltd, 2022
- Glomerulonephritis - Pipeline by InSilico Medicine, 2022
- Glomerulonephritis - Pipeline by Integral Molecular Inc, 2022
- Glomerulonephritis - Pipeline by INVENT Pharmaceuticals Inc, 2022
- Glomerulonephritis - Pipeline by Ionis Pharmaceuticals Inc, 2022
- Glomerulonephritis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Glomerulonephritis - Pipeline by KeyMed Biosciences Inc, 2022
- Glomerulonephritis - Pipeline by Mallinckrodt Plc, 2022
- Glomerulonephritis - Pipeline by MorphoSys AG, 2022
- Glomerulonephritis - Pipeline by Novartis AG, 2022
- Glomerulonephritis - Pipeline by NovelMed Therapeutics Inc, 2022
- Glomerulonephritis - Pipeline by Oak Hill Bio Inc, 2022
- Glomerulonephritis - Pipeline by Omeros Corp, 2022
- Glomerulonephritis - Pipeline by Oraxion Therapeutics Inc, 2022
- Glomerulonephritis - Pipeline by Pfizer Inc, 2022
- Glomerulonephritis - Pipeline by PlateletBio, 2022
- Glomerulonephritis - Pipeline by Polyneuron Pharmaceuticals AG, 2022
- Glomerulonephritis - Pipeline by Puretech Health Plc, 2022
- Glomerulonephritis - Pipeline by Ra Pharmaceuticals Inc, 2022
- Glomerulonephritis - Pipeline by Reata Pharmaceuticals Inc, 2022
- Glomerulonephritis - Pipeline by RemeGen Co Ltd, 2022
- Glomerulonephritis - Pipeline by River 3 Renal Corp, 2022
- Glomerulonephritis - Pipeline by Rohto Pharmaceutical Co Ltd, 2022
- Glomerulonephritis - Pipeline by Shanghai Alebund Pharmaceuticals Ltd, 2022
- Glomerulonephritis - Pipeline by Shenzhen Evergreen Therapeutics Co Ltd, 2022
- Glomerulonephritis - Pipeline by Slate Bio Inc, 2022
- Glomerulonephritis - Pipeline by Sujana Biotech, LLC, 2022
- Glomerulonephritis - Pipeline by Surrozen Inc, 2022
- Glomerulonephritis - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Glomerulonephritis - Pipeline by Transcenta Holding Ltd, 2022
- Glomerulonephritis - Pipeline by Travere Therapeutics Inc, 2022
- Glomerulonephritis - Pipeline by Vera Therapeutics Inc, 2022
- Glomerulonephritis - Pipeline by Vertex Pharmaceuticals Inc, 2022
- Glomerulonephritis - Pipeline by Visterra Inc, 2022
- Glomerulonephritis - Pipeline by Wuhan LL Science and Technology Development Co Ltd, 2022
- Glomerulonephritis - Pipeline by ZyVersa Therapeutics Inc, 2022
- Glomerulonephritis - Dormant Projects, 2022
- Glomerulonephritis - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Glomerulonephritis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AKSO Biopharmaceutical Inc
- Alexion Pharmaceuticals Inc
- Algomedix Inc
- Alnylam Pharmaceuticals Inc
- Amyndas Pharmaceuticals LLC
- Anagenics Ltd
- Angion Biomedica Corp
- Apellis Pharmaceuticals Inc
- Argenx SE
- Arrowhead Pharmaceuticals Inc
- Bayer AG
- BioCryst Pharmaceuticals Inc
- Biogen Inc
- Boehringer Ingelheim International GmbH
- Cabaletta Bio Inc
- Calliditas Therapeutics AB
- Ceptur Therapeutics Inc
- Certa Therapeutics Pty Ltd
- ChemoCentryx Inc
- Chinook Therapeutics Inc
- Coegin Pharma AS
- Cytodesign Inc
- Delta 4 GmbH
- DiaMedica Therapeutics Inc
- Dimerix Ltd
- Eledon Pharmaceuticals Inc
- Eli Lilly and Co
- Ergon Pharmaceuticals LLC
- Generian Pharmaceuticals Inc
- Goldfinch Bio Inc
- HanAll Biopharma Co Ltd
- Horizon Therapeutics Plc
- IGAN Biosciences Inc
- ImmunoWork LLC
- Inmagene Biopharmaceuticals Ltd
- InSilico Medicine
- Integral Molecular Inc
- INVENT Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc
- Jiangsu Hengrui Medicine Co Ltd
- KeyMed Biosciences Inc
- Mallinckrodt Plc
- MorphoSys AG
- Novartis AG
- NovelMed Therapeutics Inc
- Oak Hill Bio Inc
- Omeros Corp
- Oraxion Therapeutics Inc
- Pfizer Inc
- PlateletBio
- Polyneuron Pharmaceuticals AG
- Puretech Health Plc
- Ra Pharmaceuticals Inc
- Reata Pharmaceuticals Inc
- RemeGen Co Ltd
- River 3 Renal Corp
- Rohto Pharmaceutical Co Ltd
- Shanghai Alebund Pharmaceuticals Ltd
- Shenzhen Evergreen Therapeutics Co Ltd
- Slate Bio Inc
- Sujana Biotech, LLC
- Surrozen Inc
- Takeda Pharmaceutical Co Ltd
- Transcenta Holding Ltd
- Travere Therapeutics Inc
- Vera Therapeutics Inc
- Vertex Pharmaceuticals Inc
- Visterra Inc
- Wuhan LL Science and Technology Development Co Ltd
- ZyVersa Therapeutics Inc
